High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer
HGAS was associated with enhanced cell cycle pathway and immune activity in BC. These results suggest that CCNB2 is a potential key therapeutic target in BC patients.
Authors
- Shunshun Zhang (ORCID: https://orcid.org/0000-0002-4540-8590)
- Qinan Yin (ORCID: https://orcid.org/0000-0001-8560-5751)
- Xuewei Zheng (ORCID: https://orcid.org/0000-0002-2887-8013)
- Yirui Dong
- Wenbin Huang (ORCID: https://orcid.org/0000-0001-9093-8091)
- Jing Liang (ORCID: https://orcid.org/0000-0001-5533-2107)
- Jiayu Zheng
- Li Zeng (ORCID: https://orcid.org/0000-0002-6547-2602)
- Xin Xiong (ORCID: https://orcid.org/0000-0001-7554-6823)
- Haodi Ma
Institutions
- Nanchang University (CN)
- Henan University of Science and Technology (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2024-08-23
- DOI
- https://doi.org/10.31083/j.fbl2908308
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00